Finance

Lists
Q3 2026 earnings • released • EPS beat +623.00% • Revenue beat +2.03%
See results
ALNY:NASDAQ
Alnylam Pharmaceuticals, Inc.
$158.00
-4.24%
(-7.00) 1D
$159.99
+1.26% (+1.99)
After hours
Closed: Nov 2, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ALNY...
Open
$163.10
High
$163.90
Low
$156.00
Mkt. cap
21.16B
Avg. vol.
1.86M
Volume
0.00
P/E ratio
8.00
52-wk high
$479.79
52-wk low
$156.00
EPS
$19.75
Beta
0.28
Shares outstanding
133.94M
No. of employees
2K
Open
$163.10
High
$163.90
Low
$156.00
Mkt. cap
21.16B
Avg. vol.
1.86M
Volume
0.00
P/E ratio
8.00
52-wk high
$479.79
52-wk low
$156.00
EPS
$19.75
Beta
0.28
Shares outstanding
133.94M
No. of employees
2K
News stories
From web sources and news partners
Profile
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
About Alnylam Pharmaceuticals, Inc.
CEO-
Employees2.5K
FoundedJun 14, 2002
Headquarters-
SectorBiotechnology
Websitealnylam.com
Analyst ratings
Based on 25 analysts giving stock ratings to ALNY in the past 3 months
Buy
Buy
17
Hold
8
Sell
0
12-month forecast
Based on 25 Wall Street analysts offering 12 month price targets for ALNY in the last 3 months.
Highest
Current $158.00
$455.00 (+187.97%)
Average
$318.44 (+101.54%)
Lowest
$220.00 (+39.24%)
Analyst
Recommendation
Action
Price target
Projected
Date
Whitney Ijem
Canaccord Genuity
Buy
Maintained
$323.00
+104.4%
11/02/2026
Danielle Brill
Truist Financial
Hold
Downgraded
$225.00
+42.4%
11/02/2026
Eliana Merle
Barclays
Buy
Maintained
$380.00
+140.5%
11/02/2026
Ilya Zubkov
Freedom Capital Markets
Buy
Maintained
$350.00
+121.5%
10/30/2026
Michael Ulz
Morgan Stanley
Hold
Reiterated
$240.00
+51.9%
10/30/2026
Ritu Baral
TD Cowen
Buy
Reiterated
$354.00
+124.1%
10/30/2026
Salveen Richter
Goldman Sachs
Buy
Maintained
$320.00
+102.5%
10/30/2026
William Pickering
Bernstein
Hold
Downgraded
-
-
10/30/2026
Joon Lee
UBS
Buy
Maintained
$329.00
+108.2%
10/30/2026
Edward Tenthoff
Piper Sandler
Buy
Reiterated
$410.00
+159.5%
10/30/2026
Luca Issi
RBC Capital
Buy
Reiterated
$280.00
+77.2%
10/29/2026
Derek Archila
Wells Fargo
Hold
Maintained
$220.00
+39.2%
10/29/2026
Tazeen Ahmad
Bank of America Securities
Buy
Reiterated
$287.00
+81.6%
10/29/2026
Martin Auster
Raymond James
Buy
Maintained
$315.00
+99.4%
10/30/2026
Keay Nakae
Chardan Capital
Buy
Maintained
$375.00
+137.3%
10/30/2026
Paul Matteis
Stifel Nicolaus
Hold
Downgraded
$225.00
+42.4%
10/29/2026
Faisal Khurshid
Jefferies
Hold
Maintained
$250.00
+58.2%
10/29/2026
Patrick Trucchio
H.C. Wainwright
Buy
Reiterated
$455.00
+188%
10/30/2026
Unknown Analyst
Guggenheim
Hold
Reiterated
-
-
10/29/2026
David Lebowitz
BMO Capital
Buy
Maintained
$290.00
+83.5%
10/27/2026
Eric Joseph
Citi
Buy
Maintained
$320.00
+102.5%
10/26/2026
Unknown Analyst
Wells Fargo
Hold
Reiterated
$253.00
+60.1%
10/14/2026
Olivia Brayer
Cantor Fitzgerald
Hold
Maintained
$325.00
+105.7%
09/30/2026
Jessica Fye
J.P. Morgan
Buy
Reiterated
$369.00
+133.5%
09/30/2026
Jeffrey Walch
Bernstein
Buy
Maintained
$376.00
+138%
09/25/2026
Joseph Stringer
Needham
Buy
Maintained
$357.00
+125.9%
09/17/2026
Cory Kasimov
Evercore ISI
Buy
Maintained
$325.20
+105.8%
08/31/2026
Unknown Analyst
BMO Capital
Buy
Initiated
$318.00
+101.3%
08/18/2026
Kostas Biliouris
Oppenheimer
Buy
Maintained
$350.00
+121.5%
07/31/2026
Myles Minter
William Blair
Buy
Maintained
-
-
07/30/2026
Unknown Analyst
J.P. Morgan
Buy
Maintained
$420.00
+165.8%
05/20/2026
Unknown Analyst
Citi
Buy
Initiated
$380.00
+140.5%
05/19/2026
Tiago Fauth
Raymond James
Hold
Maintained
$377.00
+138.6%
05/01/2026
Last report
Oct 29, 2026
Fiscal period
Q3 2026
$16.26 / $2.25
+623.00%beat
Revenue / Est. (USD)
1.46B / 1.43B
+2.03%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
1.10B
1.17B
1.29B
1.46B
Cost of goods sold
267.72M
211.12M
298.45M
361.75M
Cost of revenue
267.72M
211.12M
298.45M
361.75M
Research and development expenses
372.22M
364.87M
413.13M
408.54M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
325.37M
322.55M
347.92M
342.00M
Operating expense
697.59M
687.42M
761.06M
750.54M
Total operating expenses
965.32M
898.54M
1.06B
1.11B
Operating income
131.72M
268.64M
231.44M
345.80M
Other non operating income
92.98M
-4.30M
273.00K
3.44M
EBT including unusual items
161.14M
221.65M
177.81M
295.81M
EBT excluding unusual items
121.99M
221.65M
177.81M
295.81M
Income tax expense
-25.28M
15.66M
13.31M
-1.87B
Effective tax rate
-15.69%
7.07%
7.49%
-632.68%
Other operating expenses
-
-
-
-
Net income
186.42M
205.99M
164.49M
2.17B
Net profit margin
16.99%
17.65%
12.74%
148.64%
Earnings per share
1.25
1.99
1.84
16.26
Interest and investment income
26.63M
26.60M
28.14M
30.94M
Interest expense
-129.34M
-69.29M
-82.05M
-84.37M
Net interest expenses
-102.71M
-42.69M
-53.91M
-53.43M
Depreciation and amortization charges
-
-
-
-
EBITDA
145.22M
282.19M
245.34M
360.27M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps